Clearmind Medicine Inc. CMND 深 沪
交易中 03-27 10:03:17 美东时间
0.7376
+0.001
+0.08%
华盛通- 最 高1.27
- 今 开0.72
- 成交量 3471股
- 最 低 0.5949
- 昨 收 0.737
- 总市值 0
- 52周最高 3.2499
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.0661
- 委 比 33.33%
- 总股本 --
- 历史最高 6.80
- 量 比 0
- 振 幅 91.60%
- 历史最低 0.03
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearmind Medicine's MEAI Included In Bipartisan Legislation In U.S. Congress
The Expanding Veterans' Access to Emerging Treatments Act of 2026 (H.R. 7091) directs the Department of Veterans Affairs (VA) to establish an investigational research and extended access treatment program for innovative
02-03 21:04
Clearmind Medicine Completes Enrollment For Second Cohort Of Phase I/IIa AUD Trial Of CMND-100
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major
2025-12-16 21:46
Why Did Clearmind Medicine Shares Plunge 29% After Hours?
Clearmind Medicine shares dropped in after-hours trading following the company's announcement of a 1-for-40 reverse stock split.
2025-12-11 16:28
Why Did Clearmind Medicine Shares Jump 7% In Pre-Market Trading?
Clearmind Medicine rose 7.09% in pre-market trading after announcing enrollment of first patient in trial for alcohol use disorder.
2025-11-26 17:32
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
Clearmind Medicine expands its Phase I/IIa clinical trial for CMND-100, a psychedelic-derived drug for Alcohol Use Disorder, adding Tel Aviv Sourasky Medical Center as a new site, joining Yale and Johns Hopkins.
2025-06-23 11:55
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
Clearmind Medicine has partnered with a leading government affairs firm to advance psychedelic-based therapies, aiming to influence policymakers and ensure safe access while progressing treatments for mental health conditions.
2025-06-12 13:25
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
Clearmind Medicine Inc. has enrolled the first patient in its Phase I/IIa trial for CMND-100, an oral drug candidate targeting Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine, aims to assess the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption. This milestone marks a significant step toward addressing the unmet medical needs of millions affected by AUD.
2025-06-05 11:32
SciSparc Shares Are Soaring Monday: What's Going On?
SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic therapy targeting cocaine addiction.
2025-03-10 23:49
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotech firm based in Vancouver, has been granted a new patent by the United States Patent and Trademark Office. As the company stated in a press release, this approval marks a significant milestone in Clearmind's efforts to develop psychedelic...
2024-08-24 01:17
